1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Africa Cancer Targeted Therapy Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Africa Cancer Targeted Therapy Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Africa Cancer Targeted Therapy Market Regional Analysis
6.2 Africa Cancer Targeted Therapy Market Revenue 2021-2031 (US$ Million)
6.3 Africa Cancer Targeted Therapy Market Forecast Analysis
7. Africa Cancer Targeted Therapy Market Analysis – by Therapy Type
7.1 Monoclonal Antibodies
- 7.1.1 Overview
- 7.1.2 Monoclonal Antibodies: Africa Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Tyrosine Kinase Inhibitors
- 7.2.1 Overview
- 7.2.2 Tyrosine Kinase Inhibitors: Africa Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Immune Checkpoint Inhibitors
- 7.3.1 Overview
- 7.3.2 Immune Checkpoint Inhibitors: Africa Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Cancer Vaccines
- 7.4.1 Overview
- 7.4.2 Cancer Vaccines: Africa Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Gene Therapy
- 7.5.1 Overview
- 7.5.2 Gene Therapy: Africa Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.6 Other Therapy Types
- 7.6.1 Overview
- 7.6.2 Other Therapy Types: Africa Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8. Africa Cancer Targeted Therapy Market Analysis – by Indication
8.1 Blood Cancer
- 8.1.1 Overview
- 8.1.2 Blood Cancer: Africa Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Lung Cancer
- 8.2.1 Overview
- 8.2.2 Lung Cancer: Africa Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Breast Cancer
- 8.3.1 Overview
- 8.3.2 Breast Cancer: Africa Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Colorectum Cancer
- 8.4.1 Overview
- 8.4.2 Colorectum Cancer: Africa Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.5 Prostate Cancer
- 8.5.1 Overview
- 8.5.2 Prostate Cancer: Africa Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Stomach Cancer
- 8.6.1 Overview
- 8.6.2 Stomach Cancer: Africa Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.7 Cervical Cancer
- 8.7.1 Overview
- 8.7.2 Cervical Cancer: Africa Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.8 Liver and Intrahepatic Bile Duct Cancer
- 8.8.1 Overview
- 8.8.2 Liver and Intrahepatic Bile Duct Cancer: Africa Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.9 Thyroid Cancer
- 8.9.1 Overview
- 8.9.2 Thyroid Cancer: Africa Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.10 Other Indications
- 8.10.1 Overview
- 8.10.2 Other Indications: Africa Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9. Africa Cancer Targeted Therapy Market Analysis – by End User
9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: Africa Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: Africa Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Online Stores
- 9.3.1 Overview
- 9.3.2 Online Stores: Africa Cancer Targeted Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
10. Africa Cancer Targeted Therapy Market – Africa Analysis
10.1 Overview
10.2 Africa
- 10.2.1 Africa Cancer Targeted Therapy Market Breakdown, by Key
Country, 2025 and 2031 (%)
- 10.2.1.1 Africa Cancer Targeted Therapy Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 Egypt:
Africa Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.1.1 Egypt: Africa Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.1.2 Egypt: Africa Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.1.3 Egypt: Africa Cancer Targeted Therapy Market Breakdown, by End User
- 10.2.1.2 South Africa:
Africa Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.2.1 South Africa: Africa Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.2.2 South Africa: Africa Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.2.3 South Africa: Africa Cancer Targeted Therapy Market Breakdown, by End User
- 10.2.1.3 Nigeria:
Africa Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.3.1 Nigeria: Africa Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.3.2 Nigeria: Africa Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.3.3 Nigeria: Africa Cancer Targeted Therapy Market Breakdown, by End User
- 10.2.1.4 and Algeria:
Africa Cancer Targeted Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.4.1 and Algeria: Africa Cancer Targeted Therapy Market Breakdown, by Therapy Type
- 10.2.1.4.2 and Algeria: Africa Cancer Targeted Therapy Market Breakdown, by Indication
- 10.2.1.4.3 and Algeria: Africa Cancer Targeted Therapy Market Breakdown, by End User
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Astellas Pharma Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Eli Lilly and Co
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Novartis AG
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Merck KGaA
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Johnson & Johnson
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 AstraZeneca
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Pfizer Inc
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Bristol Myers Squibb
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 F. Hoffmann-La Roche Ltd
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
13.11 AbbVie
- 13.11.1 Key Facts
- 13.11.2 Business Description
- 13.11.3 Products and Services
- 13.11.4 Financial Overview
- 13.11.5 SWOT Analysis
- 13.11.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations